Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1644)	6/15/2003 6:23:22 AM
From: Icebrg	Read Replies (1) \| Respond to of 3044

Proteasome Inhibition: A New Pathway in Cancer Therapy Julian Adams, PhD; Heinz-Josef Lenz, MD; Paul Richardson, MD; Sundar Jagannath, MD; David Schenkein, MD Slides with transcript and RealAudio: medscape.com\|5459902172356847712/184161392/6/7001/7001/7002/7002/7001/-1 1. Introduction and Current State of Multiple Myeloma Therapy by David Schenkein, MD Introduction Current State of Multiple Myeloma Therapy 2 The Proteasome: Structure, Function, and Role in the Cell by Julian Adams, PhD The Proteasome Characteristics and Forms of Proteasome Bortezomib Structure and Binding Proteasome and Cancer Mechanisms of Action of Bortezomib Conclusions 3 Clinical Update: Proteasome Inhibitors in Solid Tumors by Heinz-Josef Lenz, MD Proteasome and Tumors An Overview of Bortezomib (PS-341) and Tumor Cell Growth Bortezomib and Pancreatic Cancer Study 027: Solid Tumors Treated With Bortezomib and Gemcitabine Bortezomib in Prostate and Colorectal Cancer Study 028: Bortezomib and Irinotecan in Advanced Solid Tumors Bortezomib, 5-FU, and Leucovorin Clinical Trial: Study Designs and Patient Characteristics Clinical Trial Results Summary and Conclusion 4 Clinical Update: Results of the Phase II SUMMIT Trial by Paul Richardson, MD The SUMMIT Trial Study Design and Patient Characteristics Treatment Response Adverse Effects Quality of Life and Other Benefits of Treatment Pharmacogenomics Conclusions and Future Directions 5 Clinical Update: Results of the Phase II CREST Trial by Sundar Jagannath, MD The CREST Trial Study Rationale and Design Determination of Response Patient and Disease Characteristics Patient Response Adverse Effects Conclusions 6 Proteasome Inhibition as a Therapy for Multiple Myeloma: Future Directions and Closing Remarks by David Schenkein, MD 7 Post Test and Evaluation